Total amount raised
$529 Million
Latest funding date
03/01/2024
Location
Alumis has successfully raised funding over six rounds, with the latest being a Post-IPO Equity round. The company is backed by 12 investors, including notable names like Foresite Capital and Samsara BioCapital.
Keep reading to explore the intricacies of Alumis' fundraising journey and the investors supporting this precision medicine company focused on autoimmune disorders.
What Is Alumis?
Alumis is a precision medicine company based in San Francisco, California, dedicated to the discovery, development, and treatment of autoimmune disorders. The company operates in multiple industries, including Biotechnology, Health Care, Life Science, Medical, and Precision Medicine.
With an employee count between 101-250, Alumis is committed to transforming the treatment of immune-mediated diseases through advanced, targeted therapies. The company leverages a proprietary data analytics platform to drive its precision approach.
How Much Funding Has Alumis Raised?
- Series A
- Amount Raised: USD 70,000,000
- Date: May 2021
- Lead Investors: Foresite Capital
- Valuation at Round: Not publicly disclosed
- Motivation Behind the Round: To support the initial development of their precision medicine platform and early-stage pipeline programs.
- Series B
- Amount Raised: USD 200,000,000
- Date: January 2022
- Lead Investors: Matrix Capital Management
- Valuation at Round: Not publicly disclosed
- Motivation Behind the Round: To advance clinical trials and expand the company's research and development capabilities.
- Series C
- Amount Raised: USD 259,000,000
- Date: March 2024
- Lead Investors: Foresite Capital, Samsara BioCapital, venBio Partners
- Valuation at Round: Not publicly disclosed
- Motivation Behind the Round: To support the further advancement of precision data analytics, explore ESK-001’s potential in other autoimmune indications, and develop A-005 and other internal pipeline programs.
- Post-IPO Equity
- Amount Raised: USD 40,000,000
- Date: July 2024
- Valuation at Round: Not publicly disclosed
- Motivation Behind the Round: To bolster the company's financial position post-IPO and support ongoing clinical trials.
- Secondary Market
- Amount Raised: USD 3,094,730
- Date: November 2025
- Lead Investors: Foresite Capital
- Valuation at Round: Not publicly disclosed
- Motivation Behind the Round: To provide liquidity for early investors and employees.
Total Amount Raised: USD 572,094,730. Current Valuation: Not publicly disclosed.
Key Investors
- Foresite Capital
- Details: Foresite Capital is a venture capital firm that invests in healthcare and life sciences companies. They have been a lead investor in multiple funding rounds for Alumis.
- Investment Focus Areas: Biotechnology, Health Care, Life Sciences
- Notable Investments: Alumis, Relay Therapeutics, 10x Genomics
- Samsara BioCapital
- Details: Samsara BioCapital is a venture capital firm focused on investing in early-stage life sciences companies. They have participated in multiple funding rounds for Alumis.
- Investment Focus Areas: Biotechnology, Pharmaceuticals, Medical Devices
- Notable Investments: Alumis, Allakos, Encoded Therapeutics
- venBio Partners
- Details: venBio Partners is a life sciences investment firm that partners with industry leaders to develop innovative therapies. They are an investor in Alumis.
- Investment Focus Areas: Biotechnology, Pharmaceuticals, Medical Devices
- Notable Investments: Alumis, Arcutis Biotherapeutics, Apellis Pharmaceuticals
- Matrix Capital Management
- Details: Matrix Capital Management is a private investment firm that focuses on long-term investments in public and private companies. They have invested in Alumis.
- Investment Focus Areas: Technology, Healthcare, Consumer
- Notable Investments: Alumis, Moderna, Square
- Cormorant Asset Management
- Details: Cormorant Asset Management is a healthcare-focused investment firm that invests in public and private companies. They participated in the Series C funding round for Alumis.
- Investment Focus Areas: Biotechnology, Pharmaceuticals, Medical Devices
- Notable Investments: Alumis, CRISPR Therapeutics, Intellia Therapeutics
What's Next for Alumis?
Alumis stands at the cusp of significant opportunities, particularly with its lead candidate, ESK-001, targeting conditions like moderate to severe plaque psoriasis and systemic lupus erythematosus. The potential market for these treatments is vast, given the millions affected globally. Additionally, the development of A-005 for neuroinflammatory and neurodegenerative diseases opens doors to address substantial unmet medical needs.
Future fundraising efforts could see Alumis pursuing additional Series D rounds or strategic partnerships with larger pharmaceutical companies. The precision medicine approach and promising clinical trials may also pave the way for an IPO, attracting further investment.
However, challenges such as clinical trial risks, regulatory hurdles, and competition from other biopharmaceutical companies loom large. Navigating these obstacles will be crucial for Alumis as it continues to advance its innovative therapies.
Use Clay to Get Funding Data
Sales professionals, take your strategy to the next level by leveraging Clay’s platform to access comprehensive fundraising data on companies like Alumis and gather other critical business insights.
Sign up for free to start exploring the wealth of information available at your fingertips and drive your sales success.
